Abstracts tagged "survival"

Abstract Number: 1375 • ACR Convergence 2021
Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
Nancy Maltez¹, Mianbo Wang², Georges Wells³, Peter Tugwell¹, Murray Baron⁴, Zora Marjanovic⁵, Pauline Lansiaux⁶, Dominique Farge⁶ and Marie Hudson⁷, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Jewish General Hospital, Montréal, QC, Canada, ⁵Hopital Saint-Antoine, Paris, France, ⁶8. Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France, Paris, France, ⁷McGill University, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a chronic disease characterized by vasculopathy, inflammation and fibrosis. Rheumatologists have limited options to effectively treat rapidly progressive disease. There…
Abstract Number: 1918 • ACR Convergence 2021
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Rebecca Brooks¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Gail Kerr³, Andreas Reimold⁴, Gary Kunkel⁵, Katherine Wysham⁶, Namrata Singh⁷, Deana Lazaro⁸, Paul Monach⁹, Jill Poole¹, Dana Ascherman¹⁰, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁴University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁵University of Utah, Salt Lake City, UT, ⁶VA Puget Sound/University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA, ⁸VA New York Harbor Healthcare system, Brooklyn, NY, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Long-term outcomes following a diagnosis of rheumatoid arthritis associated interstitial lung disease (RA-ILD) are poor, with a median survival estimated between 3 to 8…
Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Jean-Guillaume Letarouilly¹, Benoit Flachaire ², Céline Labadie ³, Jérémie Sellam ⁴, Pascal Richette ⁵, Philippe Dieudé ⁶, Pascal Claudepierre ⁷, Bruno Fautrel ⁸, Eric Houvenagel ⁹, Chi Duc Nguyen ¹⁰, Marie-Hélène Guyot ¹¹, Nicolas Segaud ¹², Frédéric Maury ¹³, Laurent Marguerie ¹⁴, Xavier Deprez ¹⁵, Jean-Hugues Salmon ¹⁶, Guy Baudens ¹⁷, Elisabeth Gervais ¹⁸, Isabelle Chary-Valckenaere ¹⁹, Pierre Lafforgue ²⁰, Damien Loeuille ²¹, Christophe Richez ²², Thao Pham ²⁰ and René-Marc Flipo ²³, ¹University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ²Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁵Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁶Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁷Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁸Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹⁰Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹¹Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹²Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹³Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁴Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁵Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁶Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁷Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ¹⁸CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁹Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²⁰Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²¹Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²²Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²³University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].